VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 5, 2012) - Abattis Biologix Corporation (CNSX:FLU) ("Abattis" or the "Company") announces that effective as of the opening of trading on September 11, 2012, the Company will consolidate its common share capital on the basis of five (5) pre-consolidation common shares held for one new post-consolidation common share (5:1), such that the 61,767,823 issued and outstanding common shares of the Company will consolidate into approximately 12,353,564 common shares. Any fractional shares resulting from the consolidation comprising less than 1/2 common share will be rounded down to the nearest whole number, and any fractional shares comprising greater than or equal to 1/2 common share will be converted into one whole common share.

Concurrent with the share consolidation, the Company will also be changing its name to "Abattis Bioceuticals Corp.". The Company's trading symbol on the CNSX will remain unchanged (FLU).

The share consolidation was approved by the shareholders of the Company at the annual general and special meeting held on July 23, 2012.

Letters of transmittal with respect to the consolidation and name change will be mailed to all registered shareholders of the Company. All registered shareholders of the Company will be required to send their certificates representing pre-consolidation common shares with a properly executed letter of transmittal to the Company's transfer agent, Computershare Investor Services Inc. ("Computershare"). Additional copies of letters of transmittal can be obtained from, and inquiries regarding letters of transmittal can be directed to Computershare's Corporate Actions department (by phone at 1-800-564-6253 or by e-mail to [ corporateactions@computershare.com ]).

The Company has also changed its head office location to: Suite 1000 - 355 Burrard Street, Vancouver, BC V6C 2G8.

ON BEHALF OF THE BOARD OF DIRECTORS OF ABATTIS BIOLOGIX CORPORATION

Mike Withrow, President & CEO

Contributing Sources

---

Market Wire